<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35064812</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>23</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>24</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1432-1459</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>269</Volume>
            <Issue>6</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>Journal of neurology</Title>
          <ISOAbbreviation>J Neurol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Neuromyelitis optica spectrum disorder following COVID-19 infection with increase in pre-existing anti-aquaporin-4 antibodies.</ArticleTitle>
        <Pagination>
          <StartPage>2850</StartPage>
          <EndPage>2853</EndPage>
          <MedlinePgn>2850-2853</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s00415-022-10972-9</ELocationID>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Jentzer</LastName>
            <ForeName>Alexandre</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Immunology, Saint Eloi Montpellier University Hospital, Montpellier University, 80 Avenue Augustin FLICHE, 34 295, cedex 5, Montpellier, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Carra-Dallière</LastName>
            <ForeName>Clarisse</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Gui de Chauliac Montpellier University Hospital, Montpellier University, Montpellier, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lozano</LastName>
            <ForeName>Claire</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Immunology, Saint Eloi Montpellier University Hospital, Montpellier University, 80 Avenue Augustin FLICHE, 34 295, cedex 5, Montpellier, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Riviere</LastName>
            <ForeName>Sophie</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Internal Medicine, Saint Eloi Montpellier University Hospital, Montpellier University, Montpellier, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Darmon</LastName>
            <ForeName>Olivier</ForeName>
            <Initials>O</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Internal Medicine, Saint Eloi Montpellier University Hospital, Montpellier University, Montpellier, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ayrignac</LastName>
            <ForeName>Xavier</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Gui de Chauliac Montpellier University Hospital, Montpellier University, Montpellier, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Labauge</LastName>
            <ForeName>Pierre</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Gui de Chauliac Montpellier University Hospital, Montpellier University, Montpellier, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Vincent</LastName>
            <ForeName>Thierry</ForeName>
            <Initials>T</Initials>
            <Identifier Source="ORCID">0000-0001-5629-179X</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Immunology, Saint Eloi Montpellier University Hospital, Montpellier University, 80 Avenue Augustin FLICHE, 34 295, cedex 5, Montpellier, France. t-vincent@chu-montpellier.fr.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016422">Letter</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>01</Month>
          <Day>22</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>J Neurol</MedlineTA>
        <NlmUniqueID>0423161</NlmUniqueID>
        <ISSNLinking>0340-5354</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D051401">Aquaporin 4</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D001323">Autoantibodies</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D051401" MajorTopicYN="N">Aquaporin 4</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001323" MajorTopicYN="N">Autoantibodies</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009471" MajorTopicYN="Y">Neuromyelitis Optica</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>The authors declared no potential conflict of interest with respect to the research, authorship, and publication of this article.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>23</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>13</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>12</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>23</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>22</Day>
          <Hour>12</Hour>
          <Minute>5</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35064812</ArticleId>
        <ArticleId IdType="pmc">PMC8783181</ArticleId>
        <ArticleId IdType="doi">10.1007/s00415-022-10972-9</ArticleId>
        <ArticleId IdType="pii">10.1007/s00415-022-10972-9</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med. 2005;202:473–477. doi: 10.1084/jem.20050304.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1084/jem.20050304</ArticleId>
            <ArticleId IdType="pmc">PMC2212860</ArticleId>
            <ArticleId IdType="pubmed">16087714</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jarius S, Paul F, Weinshenker BG, Levy M, Kim HJ, Wildemann B. Neuromyelitis optica. Nat Rev Dis Primers. 2020;6:85. doi: 10.1038/s41572-020-0214-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41572-020-0214-9</ArticleId>
            <ArticleId IdType="pubmed">33093467</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mao L, Jin H, Wang M, Hu Y, Chen S, He Q, Chang J, Hong C, Zhou Y, Wang D, Miao X, Li Y, Hu B. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol. 2020;77:683–690. doi: 10.1001/jamaneurol.2020.1127.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamaneurol.2020.1127</ArticleId>
            <ArticleId IdType="pmc">PMC7149362</ArticleId>
            <ArticleId IdType="pubmed">32275288</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ismail II, Salama S. Association of CNS demyelination and COVID-19 infection: an updated systematic review. J Neurol. 2021 doi: 10.1007/s00415-021-10752-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00415-021-10752-x</ArticleId>
            <ArticleId IdType="pmc">PMC8359762</ArticleId>
            <ArticleId IdType="pubmed">34386902</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>De Vidi I, Boursier G, Delouche N, Portales P, Cadars E, Bouthier M, Mettling C, Lin YL, Thouvenot E, Carlander B, Camu W, Antel JP, Bar-Or A, Zephir H, Vermersch P, De Seze J, Corbeau P, Eliaou JF, Vincent T. Strategy for anti-aquaporin-4 auto-antibody identification and quantification using a new cell-based assay. Clin Immunol. 2011;138:239–246. doi: 10.1016/j.clim.2010.11.012.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.clim.2010.11.012</ArticleId>
            <ArticleId IdType="pubmed">21190899</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chanson JB, Alame M, Collongues N, Blanc F, Fleury M, Rudolf G, de Seze J, Vincent T. Evaluation of clinical interest of anti-aquaporin-4 autoantibody followup in neuromyelitis optica. Clin Dev Immunol. 2013;2013:146219. doi: 10.1155/2013/146219.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2013/146219</ArticleId>
            <ArticleId IdType="pmc">PMC3655457</ArticleId>
            <ArticleId IdType="pubmed">23710199</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu Y, Xu X, Chen Z, Duan J, Hashimoto K, Yang L, Liu C, Yang C. Nervous system involvement after infection with COVID-19 and other coronaviruses. Brain Behav Immun. 2020;87:18–22. doi: 10.1016/j.bbi.2020.03.031.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbi.2020.03.031</ArticleId>
            <ArticleId IdType="pmc">PMC7146689</ArticleId>
            <ArticleId IdType="pubmed">32240762</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Koga M, Takahashi T, Kawai M, Fujihara K, Kanda T. A serological analysis of viral and bacterial infections associated with neuromyelitis optica. J Neurol Sci. 2011;300:19–22. doi: 10.1016/j.jns.2010.10.013.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jns.2010.10.013</ArticleId>
            <ArticleId IdType="pubmed">21056429</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chakraborty S, Gonzalez J, Edwards K, Mallajosyula V, Buzzanco AS, Sherwood R, Buffone C, Kathale N, Providenza S, Xie MM, Andrews JR, Blish CA, Singh U, Dugan H, Wilson PC, Pham TD, Boyd SD, Nadeau KC, Pinsky BA, Zhang S, Memoli MJ, Taubenberger JK, Morales T, Schapiro JM, Tan GS, Jagannathan P, Wang TT. Proinflammatory IgG Fc structures in patients with severe COVID-19. Nat Immunol. 2021;22:67–73. doi: 10.1038/s41590-020-00828-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41590-020-00828-7</ArticleId>
            <ArticleId IdType="pmc">PMC8130642</ArticleId>
            <ArticleId IdType="pubmed">33169014</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goulabchand R, Vincent T, Batteux F, Eliaou JF, Guilpain P. Impact of autoantibody glycosylation in autoimmune diseases. Autoimmun Rev. 2014;13:742–750. doi: 10.1016/j.autrev.2014.02.005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.autrev.2014.02.005</ArticleId>
            <ArticleId IdType="pubmed">24657512</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35064812</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>23</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>24</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1432-1459</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>269</Volume>
            <Issue>6</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>Journal of neurology</Title>
          <ISOAbbreviation>J Neurol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Neuromyelitis optica spectrum disorder following COVID-19 infection with increase in pre-existing anti-aquaporin-4 antibodies.</ArticleTitle>
        <Pagination>
          <StartPage>2850</StartPage>
          <EndPage>2853</EndPage>
          <MedlinePgn>2850-2853</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s00415-022-10972-9</ELocationID>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Jentzer</LastName>
            <ForeName>Alexandre</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Immunology, Saint Eloi Montpellier University Hospital, Montpellier University, 80 Avenue Augustin FLICHE, 34 295, cedex 5, Montpellier, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Carra-Dallière</LastName>
            <ForeName>Clarisse</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Gui de Chauliac Montpellier University Hospital, Montpellier University, Montpellier, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lozano</LastName>
            <ForeName>Claire</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Immunology, Saint Eloi Montpellier University Hospital, Montpellier University, 80 Avenue Augustin FLICHE, 34 295, cedex 5, Montpellier, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Riviere</LastName>
            <ForeName>Sophie</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Internal Medicine, Saint Eloi Montpellier University Hospital, Montpellier University, Montpellier, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Darmon</LastName>
            <ForeName>Olivier</ForeName>
            <Initials>O</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Internal Medicine, Saint Eloi Montpellier University Hospital, Montpellier University, Montpellier, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ayrignac</LastName>
            <ForeName>Xavier</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Gui de Chauliac Montpellier University Hospital, Montpellier University, Montpellier, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Labauge</LastName>
            <ForeName>Pierre</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Gui de Chauliac Montpellier University Hospital, Montpellier University, Montpellier, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Vincent</LastName>
            <ForeName>Thierry</ForeName>
            <Initials>T</Initials>
            <Identifier Source="ORCID">0000-0001-5629-179X</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Immunology, Saint Eloi Montpellier University Hospital, Montpellier University, 80 Avenue Augustin FLICHE, 34 295, cedex 5, Montpellier, France. t-vincent@chu-montpellier.fr.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016422">Letter</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>01</Month>
          <Day>22</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>J Neurol</MedlineTA>
        <NlmUniqueID>0423161</NlmUniqueID>
        <ISSNLinking>0340-5354</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D051401">Aquaporin 4</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D001323">Autoantibodies</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D051401" MajorTopicYN="N">Aquaporin 4</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001323" MajorTopicYN="N">Autoantibodies</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009471" MajorTopicYN="Y">Neuromyelitis Optica</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>The authors declared no potential conflict of interest with respect to the research, authorship, and publication of this article.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>23</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>13</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>12</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>23</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>22</Day>
          <Hour>12</Hour>
          <Minute>5</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35064812</ArticleId>
        <ArticleId IdType="pmc">PMC8783181</ArticleId>
        <ArticleId IdType="doi">10.1007/s00415-022-10972-9</ArticleId>
        <ArticleId IdType="pii">10.1007/s00415-022-10972-9</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med. 2005;202:473–477. doi: 10.1084/jem.20050304.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1084/jem.20050304</ArticleId>
            <ArticleId IdType="pmc">PMC2212860</ArticleId>
            <ArticleId IdType="pubmed">16087714</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jarius S, Paul F, Weinshenker BG, Levy M, Kim HJ, Wildemann B. Neuromyelitis optica. Nat Rev Dis Primers. 2020;6:85. doi: 10.1038/s41572-020-0214-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41572-020-0214-9</ArticleId>
            <ArticleId IdType="pubmed">33093467</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mao L, Jin H, Wang M, Hu Y, Chen S, He Q, Chang J, Hong C, Zhou Y, Wang D, Miao X, Li Y, Hu B. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol. 2020;77:683–690. doi: 10.1001/jamaneurol.2020.1127.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamaneurol.2020.1127</ArticleId>
            <ArticleId IdType="pmc">PMC7149362</ArticleId>
            <ArticleId IdType="pubmed">32275288</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ismail II, Salama S. Association of CNS demyelination and COVID-19 infection: an updated systematic review. J Neurol. 2021 doi: 10.1007/s00415-021-10752-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00415-021-10752-x</ArticleId>
            <ArticleId IdType="pmc">PMC8359762</ArticleId>
            <ArticleId IdType="pubmed">34386902</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>De Vidi I, Boursier G, Delouche N, Portales P, Cadars E, Bouthier M, Mettling C, Lin YL, Thouvenot E, Carlander B, Camu W, Antel JP, Bar-Or A, Zephir H, Vermersch P, De Seze J, Corbeau P, Eliaou JF, Vincent T. Strategy for anti-aquaporin-4 auto-antibody identification and quantification using a new cell-based assay. Clin Immunol. 2011;138:239–246. doi: 10.1016/j.clim.2010.11.012.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.clim.2010.11.012</ArticleId>
            <ArticleId IdType="pubmed">21190899</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chanson JB, Alame M, Collongues N, Blanc F, Fleury M, Rudolf G, de Seze J, Vincent T. Evaluation of clinical interest of anti-aquaporin-4 autoantibody followup in neuromyelitis optica. Clin Dev Immunol. 2013;2013:146219. doi: 10.1155/2013/146219.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2013/146219</ArticleId>
            <ArticleId IdType="pmc">PMC3655457</ArticleId>
            <ArticleId IdType="pubmed">23710199</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu Y, Xu X, Chen Z, Duan J, Hashimoto K, Yang L, Liu C, Yang C. Nervous system involvement after infection with COVID-19 and other coronaviruses. Brain Behav Immun. 2020;87:18–22. doi: 10.1016/j.bbi.2020.03.031.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbi.2020.03.031</ArticleId>
            <ArticleId IdType="pmc">PMC7146689</ArticleId>
            <ArticleId IdType="pubmed">32240762</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Koga M, Takahashi T, Kawai M, Fujihara K, Kanda T. A serological analysis of viral and bacterial infections associated with neuromyelitis optica. J Neurol Sci. 2011;300:19–22. doi: 10.1016/j.jns.2010.10.013.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jns.2010.10.013</ArticleId>
            <ArticleId IdType="pubmed">21056429</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chakraborty S, Gonzalez J, Edwards K, Mallajosyula V, Buzzanco AS, Sherwood R, Buffone C, Kathale N, Providenza S, Xie MM, Andrews JR, Blish CA, Singh U, Dugan H, Wilson PC, Pham TD, Boyd SD, Nadeau KC, Pinsky BA, Zhang S, Memoli MJ, Taubenberger JK, Morales T, Schapiro JM, Tan GS, Jagannathan P, Wang TT. Proinflammatory IgG Fc structures in patients with severe COVID-19. Nat Immunol. 2021;22:67–73. doi: 10.1038/s41590-020-00828-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41590-020-00828-7</ArticleId>
            <ArticleId IdType="pmc">PMC8130642</ArticleId>
            <ArticleId IdType="pubmed">33169014</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goulabchand R, Vincent T, Batteux F, Eliaou JF, Guilpain P. Impact of autoantibody glycosylation in autoimmune diseases. Autoimmun Rev. 2014;13:742–750. doi: 10.1016/j.autrev.2014.02.005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.autrev.2014.02.005</ArticleId>
            <ArticleId IdType="pubmed">24657512</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
